Cathy graduated from Indiana University Southeast with a bachelor's degree in English. Over her nine-year content writing career, Cathy has developed a knack for untangling complex information and ...

Thanks to AI, data science tasks that once demanded specialized skills can now be performed faster, more accurately and at a ...

The FDA lifted the partial clinical hold on Arcellx Inc's ACLX iMMagine-1 Phase 2 Clinical Program. The move follows alignment with FDA on modifications to the iMMagine-1 trial protocol related to ...

The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate ...

This analysis is by Bloomberg Intelligence Industry Analyst Andrew Galler and Senior Associate Analyst Jack Maltby. It appeared first on the Bloomberg Terminal. Clinical trials represent a significant ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung ...

UniQure said the U.S. Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy ...

The CEO highlighted results from the REMAIN-1 Midpoint Cohort, where "Revita-treated patients lost an additional 2.5% of total body weight, while patients in the sham group regained about 10%, a ...